Ibrutinib Monotherapy in Symptomatic, Treatment-Naive Patients With WM

Key Findings

• ●Ibrutinib highly active as primary therapy in treatment-naive WM
• ●CXCR4 mutation status impacts response to ibrutinib
• ●Durable responses with acceptable safety profile

Referenced in (1 disease)